Prospective study of evaluating the efficacy and safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases
Latest Information Update: 07 Sep 2022
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 04 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Status changed from not yet recruiting to recruiting.
- 21 Sep 2016 New trial record